康华生物：11月7日召开董事会会议

Group 1 - The core point of the article is that Kanghua Biological announced the convening of its third board meeting via telecommunication on November 7, 2025, to review the proposal for amending the "Audit Committee Work System" [1] - For the year 2024, Kanghua Biological's revenue composition is as follows: 92.59% from non-immunization planning vaccines and 7.41% from other sources [1] Group 2 - As of the report, Kanghua Biological has a market capitalization of 10.5 billion yuan [2]